Mr. Thomas Looby reports
CONAVI MEDICAL HIGHLIGHTS COMMERCIAL LAUNCH AND SIGNIFICANT GROWTH POTENTIAL IN SHAREHOLDER LETTER
Conavi Medical Corp. has issued the following letter to shareholders from Thomas Looby, president and chief executive officer.
Dear shareholders,
Years of development have translated into U.S. commercial clinical use. Over the past year, Conavi achieved four milestones that establish the foundation for Octiv, powered by Novasight:
-
Food and Drug Administration 510(k) clearance for our next-generation hybrid imaging system;
-
Peer-reviewed clinical evidence illustrating how hybrid imaging can inform coronary treatment decisions;
-
First U.S. commercial placement and clinically beneficial cases with Octiv, followed by continuing use by multiple physicians;
-
Five-year extension of the Japan Lifeline credit facilities, moving maturity from April, 2027, to April, 2032.
Together, these achievements position Conavi to broaden physician adoption, expand hospital placements, increase recurring catheter utilization and attract strategic interest in our platform.
Clinical evidence supports broader adoption
Octiv combines the imaging depth of intravascular ultrasound with the high-resolution detail of optical coherence tomography in a single catheter to guide coronary interventions.
The 2025 U.S. acute coronary syndrome guidelines give intravascular ultrasound or optical coherence tomography a Class 1, level of evidence recommendation for procedural guidance in patients with acute coronary syndromes undergoing stent implantation in the left main artery or complex lesions. Pooled randomized evidence shows lower risks of cardiac death, heart attacks, repeat interventions and stent thrombosis with intravascular imaging guidance than with angiography alone.
Our peer-reviewed case reports illustrate how hybrid imaging can inform treatment decisions:
-
July case report: In the Journal of the Society for Cardiovascular Angiography & Interventions, physicians described using hybrid imaging to assess and treat a calcified lesion in a patient with impaired renal function, with IVUS-only imaging at selected stages helping to limit contrast exposure.
-
September case report: In Catheterization and Cardiovascular Interventions, hybrid imaging helped physicians evaluate poststent dissections and white thrombus, informing decisions on further stenting and medical management.
Octiv is in continuing clinical use
In November, we announced our first U.S. commercial placement and clinical cases, with Dr. Megha Prasad performing the initial cases. Approximately 25 clinical cases have been completed within the first two weeks of launch. Successful cases are continuing, with multiple physicians on the hospital's team now using Octiv.
Octiv incorporates enhancements focused on image quality, catheter deliverability and ease of use. Its patient interface module sits outside of the sterile field, and the catheter connection workflow is designed to simplify set-up.
Strong physician demand following launch and TCT
Following our first U.S. clinical cases, we participated in Transcatheter Cardiovascular Therapeutics 2026, where Octiv received a strong reception. Clinical presentations and physician education sessions introduced its complementary imaging capabilities to a broader audience.
Demand for Octiv systems now exceeds our current placement capacity. The response to our limited market release and initial clinical experience, as well as discussions at TCT, have surfaced strong demand for Octiv systems. We will work to meet this demand over time.
We also presented preclinical saline-based imaging results: 26 interpretable imaging pullbacks in three swine, without iodinated contrast during image acquisition. These findings support further evaluation of an approach that could help physicians manage contrast exposure.
Financial flexibility supports commercial expansion:
-
Japan Lifeline support: Backed by a relationship spanning more than a decade, the five-year extension better aligns our debt maturity with our commercial development plans.
-
$1.75-million received under Ontario's Life Sciences Scale-Up Fund, including a $1.25-million payment following FDA clearance. The agreement provides up to $2.5-million, subject to specified milestones, for eligible commercialization and manufacturing activities.
Our spending priorities are physician support, additional sites, reliable product supply and clinical evidence.
Clear priorities for growth
Our first U.S. placement and continuing clinical cases are meeting and exceeding our expectations. Our priority now is to supply this strong, initial demand through carefully selected hospital placements, physician education and support for repeat use. Four priorities will guide our execution:
-
Prioritize the next U.S. placements: focus on hospitals where physician demand, procedural needs and operational readiness align.
- Increase catheter utilization: build on continuing use at our first U.S. site by supporting repeat procedures and training additional physicians;
-
Generate clinical evidence: build on our initial commercial cases and peer-reviewed reports to support further publications showing how hybrid imaging informs treatment decisions;
-
Expand physician education and market awareness: follow-up on TCT discussions with targeted education, scientific meetings and direct engagement to help interested clinical teams integrate Octiv into their workflows.
Building a sustainable commercial business
This year, the essential pieces came together: regulatory clearance, published clinical evidence, continuing U.S. commercial use and greater financial flexibility. We now have a clear foundation for growth.
We believe disciplined execution can strengthen Conavi's commercial position, attract strategic interest in our platform and create lasting shareholder value.
To our employees, clinical collaborators, partners and shareholders, thank you for helping bring Conavi to this point. We look forward to sharing our progress as we expand Octiv's clinical and commercial reach.
Sincerely,
Thomas Looby,
President and chief executive officer,
Conavi Medical
About Conavi Medical
Corp.
Conavi is a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures. Its Octiv hybrid imaging system combines intravascular ultrasound and optical coherence tomography to provide simultaneous, co-registered images of coronary arteries using a single imaging catheter. These complementary imaging modalities provide physicians with information to support treatment decisions during coronary interventions.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.